Unmet Therapeutic Needs in Platinum-Resistant Ovarian Cancer

Rebecca C. Arend, MD, assistant professor, and associate scientist, University of Alabama-Birmingham Comprehensive Cancer Center, discusses the key unmet needs in the treatment landscape for platinum-resistant ovarian cancer.

Transcription:

0:08 | I think we've all known and believed for a long time, that this is one area of research that while we've made some, you know, some discoveries and some advancements, almost all of our ovarian cancer patients do recur, and at some point, become platinum-resistant. And we've seen tremendous advancements recently in the upfront setting for maintenance therapy in the platinum sensitive setting as far as maintenance therapy, especially in the homologous recombination deficient population.

0:40 |But I think we can all agree that we really have not seen many additional advances in the setting of platinum resistant patients, which ultimately, almost every patient becomes so this is really continues to be an area in ovarian cancer, where we need to continue to do additional preclinical studies and clinical trials in order to prolong survival in these patients.